Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06039579 · ClinicalTrials.gov registry record · Phase 2
Proof of Concept Treatment Study of Orally Administered VH4004280 or VH4011499 in HIV-1 Infected Adults
A Phase 2 study, sponsored by ViiV Healthcare.
- Completed
- Registry status
- Phase 2
- Development phase
- 44
- Enrollment target
NCT06039579 is a Phase 2 study that has completed, run by ViiV Healthcare. The registered enrollment target is 44 participants.
The verdict
NCT06039579, a Phase 2 study, has completed, sponsored by ViiV Healthcare.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 44 participants
- Enrollment target
Study Summary
The primary purpose of the study is to evaluate the antiviral activity of orally administered VH4004280 and VH4011499 monotherapy over 10 days in human immunodeficiency virus (HIV-1) infected Treatment-Naïve (TN) participants.
Interventions
- DRUG VH4004280
- DRUG VH4011499
- DRUG Antiretroviral therapy
- DRUG VH4004280 Matching Placebo
- DRUG VH4011499 Matching Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2023-10-25 |
| Est. Completion | 2024-06-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06039579
The ClinicalTrials.gov registry entry for NCT06039579 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ViiV Healthcare, which has 182 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which VH4004280 is the first listed.
NCT06039579 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06039579 about?
NCT06039579 is a clinical study titled "Proof of Concept Treatment Study of Orally Administered VH4004280 or VH4011499 in HIV-1 Infected Adults". The primary purpose of the study is to evaluate the antiviral activity of orally administered VH4004280 and VH4011499 monotherapy over 10 days in human immunodeficiency virus (HIV-1) infected Treatment-Naïve (TN) participants.
What is the current status of trial NCT06039579?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2023-10-25. Estimated completion is 2024-06-24.
What interventions are being tested in trial NCT06039579?
The interventions under investigation include: VH4004280 (DRUG), VH4011499 (DRUG), Antiretroviral therapy (DRUG), VH4004280 Matching Placebo (DRUG), VH4011499 Matching Placebo (DRUG).
Who is sponsoring clinical trial NCT06039579?
This trial is sponsored by ViiV Healthcare, which has 182 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.